<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapy-related <z:hpo ids='HP_0002863'>Myelodysplastic Syndromes</z:hpo>/<z:hpo ids='HP_0004808'>Acute Myeloid Leukemias</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) are one of the most compelling long term adverse events occurring in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> survivors treated with chemo-radiotherapy regimes </plain></SENT>
<SENT sid="1" pm="."><plain>Beside several well-described genetic lesions, a growing amount of data suggests that abnormalities in DNA methylation profile contribute to multistep secondary <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Two distinct alterations of <z:mpath ids='MPATH_458'>normal</z:mpath> DNA methylation patterns may occur in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>: a global hypomethylation resulting in <z:mp ids='MP_0008866'>chromosomal instability</z:mp> and loss of genetic integrity, and promoter specific DNA hypermethylation which leads to silencing of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes </plain></SENT>
<SENT sid="3" pm="."><plain>Cytotoxic drugs and radiation have been shown to affect tissue DNA methylation profile </plain></SENT>
<SENT sid="4" pm="."><plain>Radiation is able to induce a stable DNA hypomethylation in both target and bystander tissues </plain></SENT>
<SENT sid="5" pm="."><plain>Gene promoter methylation is a common finding in t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and has been associated to a shorter latency period from the treatment of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Among the studied genes, p15 methylation correlated to <z:mp ids='MP_0004026'>monosomy</z:mp>/deletion of chromosome 7q, suggesting that it could be a relevant event in <z:chebi fb="0" ids="22333">alkylating agent</z:chebi>-induced <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>We found frequent methylation of DAPK in the t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> group, especially in patients with a previous <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative disease</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>In patients studied for concurrent methylation of several promoters, t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were significantly more frequently hypermethylated in 2 or more promoter regions than de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> suggesting that promoter hypermethylation of genes involved in cell cycle control, <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and DNA repair pathways is a frequent finding in t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and may contribute to secondary <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>However, how the epigenetic machinery is disrupted after chemo/radiotherapy and during secondary <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> is still unknown, warranting further studies </plain></SENT>
</text></document>